Bavarian to test cancer vaccine with Roche’s checkpoint inhibitor

Denmark-based biotech company Bavarian Nordic is expanding its clinical program for experimental cancer vaccine CV301, which is to be examined in combination with a checkpoint inhibitor from Roche.

Photo: /ritzau/Philip Davali/

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Zealand Pharma indgår australsk samarbejde

Zealand Pharma har indgået et nyt samarbejde med et australsk selskab rettet mod udvikling af peptid-baserede lægemidler mod mavetarmlidelser – det danske biotekselskabs helt store fokusområde.

Related articles